Eloxatin and Confusional state - a phase IV clinical study of FDA data

Summary:

Confusional state is reported as a side effect among people who take Eloxatin (oxaliplatin), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Fluorouracil, and have Colon cancer.

The phase IV clinical study analyzes which people have Confusional state when taking Eloxatin. It is created by eHealthMe based on reports of 7,080 people who have side effects when taking Eloxatin from the FDA, and is updated regularly.

What is Eloxatin?

Eloxatin has active ingredients of oxaliplatin. eHealthMe is studying from 7,092 Eloxatin users. Check the latest studies of Eloxatin.

What is Confusional state?

Confusional state is found to be associated with 2,723 drugs and 3,320 conditions by eHealthMe. Check the latest studies of Confusional state.

On Jul, 14, 2026

7,080 people reported to have side effects when taking Eloxatin.
Among them, 91 people (1.29%) have Confusional state.

Among these 91 people:

How long have people been on Eloxatin when they have Confusional state? *

What is the gender of people who have Confusional state when taking Eloxatin? *

female: 47.78 %
male: 52.22 %

What is the age of people who have Confusional state when taking Eloxatin? *

What are other drugs people take besides Eloxatin? *

What are other side effects people have besides Confusional state? *

Fever: 20 people, 21.98%
Nausea And Vomiting: 16 people, 17.58%
Nausea (feeling of having an urge to vomit): 15 people, 16.48%
Dyspnea (difficult or laboured breathing): 12 people, 13.19%
Lung Infiltration (a substance that normally includes fluid, inflammatory exudates or cells that fill a region of lung): 12 people, 13.19%
Diarrhea: 10 people, 10.99%
Pulmonary Embolism (blockage of the main artery of the lung): 10 people, 10.99%
Drowsiness: 10 people, 10.99%
Thrombocytopenia (decrease of platelets in blood): 10 people, 10.99%
Confusion: 9 people, 9.89%

What are the existing conditions these people have? *

Colon Cancer: 17 people, 18.68%
Metastatic Gastric Cancer (cancer types can spread to the stomach from other place): 11 people, 12.09%
Ovarian Cancer (cancer of ovary): 6 people, 6.59%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 5 people, 5.49%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 4 people, 4.40%
High Blood Pressure: 3 people, 3.30%
Colorectal Cancer Stage Iii (colon and rectal cancer spreads to lymph nodes): 2 people, 2.20%
Pain In Extremity: 2 people, 2.20%
Nausea (feeling of having an urge to vomit): 2 people, 2.20%
Rectal Cancer (cancer of rectum): 2 people, 2.20%

* Approximation only. Some reports may have incomplete information.

Do you take Eloxatin and have Confusional state?

- Check whether Confusional state is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eloxatin:

Eloxatin (7,092 reports)

Confusional state treatments and more:

Confusional state (182,510 reports)

Browse all side effects of Eloxatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Confusional state:

Confusional state (2,723 drugs)

Browse all the conditions that are associated with Confusional state:

Confusional state (3,320 conditions)

Related publications that referenced our studies

Kim HJ, An SH, Cho YH, Kim SY, Lee HG, Yoon SY, "Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer", Acta Oncologica, 2013 Aug .
Wang JH, King TM, Chang MC, Hsu CW, "Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis", World journal of gastroenterology: WJG, 2012 Oct .
Kim HJ, An SH, Cho YH, Kim SY, Lee HG, Yoon SY, "Oxaliplatin-induced Torsades de pointes and long QT syndrome in a patient with gastric cancer", Acta Oncologica, 2013 Aug .
Wang JH, King TM, Chang MC, Hsu CW, "Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis", World journal of gastroenterology: WJG, 2012 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on oxaliplatin (the active ingredients of Eloxatin) and Eloxatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.